284 results
8-K
EX-99.1
d6zjl6yhdfvrmibjsq3
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
EX-99.1
oggpxcnas96jbcu1wg
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
EX-99.1
d3j9m64fny7j1546
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
8-K
2xp35n2nuu
21 Dec 23
Termination of a Material Definitive Agreement
5:00pm
8-K
EX-99.1
hkqkkvaag5o4zdvbum7x
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am
8-K
EX-99.2
mejtgen8qubdcb1 5g
29 Nov 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
2kmnad 19dercg8ya
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
EX-99.1
7w0 n9d899j
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am